期刊文献+

铜绿假单胞菌对11种抗生素的耐药性差异 被引量:2

The Resistance difference of Pseudomonas aeiuginosa to 11 antibiotics
原文传递
导出
摘要 目的探讨不同标本分离铜绿假单胞菌对11种抗生素耐药性的差异,指导临床合理使用抗生素。方法按常规方法培养分离后,经VITEK-AMS60或VITEK-II自动微生物鉴定分析仪的鉴定,用Kirty-Bauer法做药物敏感试验。结果尿液与血液之间,以及尿液与伤口分泌物之间,分离株均对所检测的11种抗生素的耐药性差异有非常显著性(P<0.01),尿液与穿刺液分离菌对除亚胺培南和美洛培南外的9种抗生素的耐药性差异有非常显著性(P<0.01),血液与穿刺液、血液与伤口分泌物和穿刺液与伤口分泌物间,除穿刺液与伤口分泌物分离菌对美洛培南的耐药性差异有显著性(P<0.05)外,其他差异均无显著性(P>0.05)。结论不同标本来源铜绿假单胞菌对哌拉西林等11种抗生素存在耐药性差异。 Objective To investigate the difference between Pseudomonas aeiuginosa strains from different types of sample with regard to their resistence to 11 antibiotics.Method After being cultrured ,the strains were identified by VITEK-AMS60 or VITEK-II Microbe ldentification System. The antibiotic susceptibility of the strains was detected by Kirty -Bauer method. Result The antibiotic resistances of the strains showed significant difference between the strains from urine and those from blood,so did the resistances between the strains from urine and those from puncture fluid (P〈0.01).There was difference between the antibiotic resistance of the strains from urine and that of the strains from wound secretion.Conclusion Pseudomonas aeruginosa from different types of samples shows different antibiotic resistances to these 11 antibiotics.
出处 《中国微生态学杂志》 CAS CSCD 2010年第4期358-359,362,共3页 Chinese Journal of Microecology
关键词 铜绿假单胞菌 抗生素 耐药性 Pseudomonas aeiuginosa Antibiotics Resistance
  • 相关文献

参考文献5

二级参考文献19

  • 1秦俊玲,韩呈武,王素兰,李春英,王路,林桂秋.10年临床感染细菌的病原学与常用抗生素的调查分析[J].中华医院感染学杂志,1996,6(4):243-245. 被引量:59
  • 2杨莉,韩立中,孙景勇,蒋晓飞,倪语星.仅黏菌素敏感的多重耐药铜绿假单胞菌分子流行病学研究[J].上海交通大学学报(医学版),2006,26(11):1298-1302. 被引量:4
  • 3Clinical and Laboratory Standards Institute. Performance standards for antimierobial susceptibility testing. Sixteenth informational supplement[S]. 2007,M100-S16.
  • 4Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance[J]. Clin Microbiol Infect, 2005,11 (Suppl 5):4-16.
  • 5[1]Craig W A. Pharmacokinetic/pharmacodynamic parameters:rationale for antibacterial dosing of mice and men[J]. Clin lnfect Dis, 1998, 26: 1-12.
  • 6[2]Nightingale C H, Murakawa T, Ambrose P G, et al. Antimicrobial pharmacodynamics in theory and clinical practice[M]. New York: Marcel Dekker, InC. 2002. 385-408.
  • 7[3]Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies[J]. Clin lnfect Dis, 2001, 33: 147-156.
  • 8Raymond DP, Pelletier SJ, Crabtee TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit[J]. Crit Care Med, 2001, 29(6): 1101-1108.
  • 9National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests[S]. 6th ed. Approved standard M2-A6(M100-S7). Wayne:NCCLS,2004.
  • 10Lautenbach E, Strom BL, Bilker WB, et al. Epidemiological investigation of fluoroquinolone in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae[J]. Clin Infect Dis, 2001,33(8):1288-1294.

共引文献262

同被引文献17

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部